Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
January 11, 2007

RXi Deploys UMass Medical School’s Nanotransporters

  • CytRx says that its subsidiary RXi Pharmaceuticals licensed RNAi intellectual property for all therapeutic applications from the University of Massachusetts Medical School (UMMS).

    The agreement includes an exclusive therapeutic license with rights to sublicense for nanotransporters, which have been shown to deliver intact RNAi to a number of tissues in animal models. The licenses are contingent upon RXi’s receipt of working capital funding in the coming months.

    Tariq M. Rana, Ph.D., professor and founding director of the program in chemical biology at UMMS and developer of the nanotransporters, reported activity with RNAi delivered with nanotransporters in mouse models at 1 milligram per kilogram. The nanotransporters are highly uniform in structure and are readily formulated by simply mixing with RNAi compounds.

    The RXi licensed technology also includes compounds for the potential treatment of amyotrophic lateral sclerosis that can be delivered locally to the central nervous system. In addition, the technology includes methods of targeting point mutations with RNAi that may be useful in targeting mutations that cause certain cancers and genetic diseases.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.